My Treatment Approach: Metastatic Endometrial Cancer

Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic endometrial cancer (mEC).

EP. 1: A Review of mEC Incidence and Prognosis and Introduction of the Clinical Case

October 11th 2022

Drs Kathleen Moore and David O’Malley share their perspectives on the incidence and prognosis of mEC, including mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) disease, and then review a scenario of a patient with dMMR mEC who was treated with first-line carboplatin/paclitaxel.

EP. 2: Expert Commentary on the Patient’s Treatment Plan

October 11th 2022

Expert oncologists discuss the patient’s first-line treatment plan and comment on how they would have approached her care.

EP. 3: First-Line Therapy for dMMR mEC: Patient Conversations and Treatment Goals

October 18th 2022

Comprehensive discussion on patient counseling, and treatment goals, and expectations for those beginning first-line chemotherapy for dMMR metastatic endometrial cancer.

EP. 4: Considerations for Second-Line and Higher Treatment of Recurrent mEC

October 18th 2022

Drs Moore and O’Malley discuss the second-line and higher targeted treatment options that they’d consider for patients with mEC who develop recurrent disease on or after chemotherapy.

EP. 5: Looking Towards the Future: Moving Targeted Therapies for mEC Into the First-Line Setting

October 25th 2022

Experts discuss ongoing clinical trials focused on moving second-line and higher targeted therapies, including immunotherapy, into the frontline setting for mEC, and then comment on how these advances might impact treatment paradigms and patient outcomes.

EP. 6: Emerging Biomarkers and Drug Targets in mEC

October 25th 2022

Shared insight into novel biomarkers and potential drug targets being explored for treatment of metastatic endometrial cancer.

EP. 7: Unmet Needs and Clinical Pearls for Metastatic Endometrial Cancer

November 1st 2022

Before closing out their conversation on endometrial cancer, Kathleen Moore and David O’Malley summarize unmet needs in the field and share a few clinical pearls on managing patients with the disease.